A Study to Assess the Efficacy and Safety of Namilumab in Participants With Chronic Pulmonary Sarcoidosis

Inclusion Criteria : * Male or female age ≥18 years * Able and willing to provide written informed consent, which includes compliance with study requirements and restrictions listed in the consent form * Greater than or equal to 6-month history of documented sarcoidosis including histological confirmation in the subject's medical records * Evidence of sarcoidosis as indicated by: a) HRCT consistent with Pulmonary Sarcoidosis AND; b) Medical Research Council Dyspnea scale \>1 (i.e., Grade 2 or more) AND; c) One or more of the following is present: i) Screening FDG-PET scan consistent with active pulmonary sarcoidosis AND SUVmax ≥ 3; ii) Recent history of worsening sarcoidosis; iii) Recent history that tapering OCS and/or ISTs resulted in an increase of pulmonary disease * Body Mass Index (BMI) ≤ 40 kg/m2 at Screening * Vaccinations for COVID-19 with completion of the primary series at least 2 weeks prior to randomization Exclusion Criteria * Hospitalized for any respiratory illness ≤ 30 days prior to or during Screening * Greater than or equal to 20% fibrosis as indicated on HRCT-scan assessed by central read prior to randomization * Hemoglobin ≤ 9.5 g/dL * Participation in another interventional clinical trial (IP/Device) within 6 months prior to Screening, during screening and throughout the duration of the study * ECG abnormalities that warrant further clinical investigation or management at Screening * Systolic blood pressure (SBP) \<90 or \>180mm Hg; Diastolic blood pr…